Valeant Pharmaceuticals Announces 2015 Annual Meeting Results

LAVAL, Quebec, May 19, 2015 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the election of eleven directors nominated at its 2015 annual meeting of shareholders today.  The detailed results of the vote for the election of directors are set out below: 

Name		For		Withheld		Broker Non-Votes
Ronald H. Farmer		259,517,209		2,064,596		12,938,661
Colleen A. Goggins		260,564,263		1,017,542		12,938,661
Robert A. Ingram		258,725,145		2,856,660		12,938,661
Anders Lönner		259,632,031		1,949,774		12,938,661
Theo Melas-Kyriazi		260,811,015		770,790		12,938,661
J. Michael Pearson		255,809,687		5,772,118		12,938,661
Robert N. Power		258,849,981		2,731,824		12,938,661
Norma A. Provencio		260,777,276		804,529		12,938,661
Howard B. Schiller		250,437,448		11,144,357		12,938,661
Katharine B. Stevenson		260,656,695		925,110		12,938,661
Jeffrey W. Ubben		260,166,082		1,415,723		12,938,661

At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation as disclosed in the proxy statement and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2016 annual meeting of shareholders.

The final vote tabulation on all matters voted on at today's meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be made available on the Company's web site, www.valeant.com.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology  and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:
Laurie W. Little
949-461-6002
[email protected]

Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO

SOURCE Valeant Pharmaceuticals International, Inc.